EGFR (Epidermal growth factor receptor)

These findings suggest that osimertinib crosses the placenta with a moderate tissue uptake, while alectinib and its metabolite M4 do not appear to be transferred to the fetus but accumulate significantly within the placental tissue. Further studies are needed to guide treatment selection for NSCLC in pregnant women.

Recent clinical trials have led to US Food and Drug Administration approval of osimertinib and alectinib as adjuvant treatments for resected pathologic stage II/III EGFR and ALK-mutated NSCLC; their use in the neoadjuvant setting remains subject to trials. These questions are the subject of two ongoing National Clinical Trials Network trials: CTIU2317-A082304-S2402-Perioperative versus Adjuvant Systemic Therapy in Patients with Resectable NSCLC (PROSPECT-Lung; ClinicalTrials.gov Identifier: NCT04267848)-and S2414-A Randomized Phase III Trial Incorporating Pathologic Response in Participants with Early-Stage NSCLC to Optimize Immunotherapy in the Adjuvant Setting (INSIGHT; ClinicalTrials.gov Identifier: NCT06498635). We discuss why there is sufficient equipoise to justify seeking answers to these two extremely important, patient-centered questions.

Overall, this integrative analysis suggests that TLXZF may exert its effects on HCC through a synergistic "multi-component-multi-target-multi-pathway" regulatory pattern, primarily involving oncogenic, inflammatory, and survival-related signaling networks. These findings are hypothesis-generating and provide an initial basis for the identification and screening of core bioactive components, key targets, and relevant pathways to support future experimental validation and clinical research.

The results suggest that carmofur and B13 are promising alternatives for therapeutic targets in drug-resistant lung cancer cells.

This article provides a target-oriented synthesis of HCC-related CAR-T-cell therapy, summarizes registered clinical studies according to antigen target, CAR design, trial phase, administration route, and available outcomes, and discusses how CAR structural evolution may influence therapeutic development in HCC. This article aims to review recent advances in CAR-T-cell therapy for hepatocellular carcinoma.

Upon reaching the tumor microenvironment, the construct undergoes dual-payload release to liberate platinum drug and the IDO-1 inhibitor NLG919, eliciting a robust immunogenic cell death cascade while simultaneously reversing immunosuppression. Furthermore, a combination with an aPD-L1 immune checkpoint blockade produces a marked synergistic antitumor response. This work establishes Pt(IV)-directed metallo-stapling as a versatile platform for precision cancer therapy, offering a generalizable strategy to chemically engineer a broad range of metalloprodrugs with enhanced tumor selectivity and biosafety.

Therefore, this study clarifies how PFAS contribute to the development of LUAD and explores the molecular pathways involved, providing crucial insights into the toxicological effects of PFAS. Furthermore, it establishes a theoretical basis for devising preventive strategies and therapeutic approaches for pulmonary diseases related to PFAS exposure.

Moreover, bakuchiol was also found to exhibit a synergistic effect against TNBC cells in association with the standard chemotherapeutic drug doxorubicin, thereby enhancing its therapeutic efficacy. These findings highlight bakuchiol as a promising HSP90-targeting natural compound with potential therapeutic benefit against TNBC, therefore making it a crucial lead for further research.

Notably, EGFR depletion by an enhanced endobody suppressed lung cancer cell proliferation and tumor growth in vivo. Collectively, endobody is an innovative class of MPDs, offering promising therapeutic potential.

NSC265450 and NSC70845 were the most potent antiproliferative agents with IC50 < 4 nM against overexpressed EGFR-TK cancer cell lines, HeLa and A549, displayed significantly much greater potencies than NSC116555, erlotinib and doxorubicin. Furthermore, molecular docking and molecular dynamics results predicted the binding action of the series to the ATP binding site of EGFR-TK; intermolecular interactions to key regions of the protein and amino acid residues are described. Prediction of pharmacokinetic and toxicity profiles of the series, and calculations of known drug indexes suggest the molecules are pharmaceutically compatible as therapeutic drug candidates.

The addition of bevacizumab to chemoimmunotherapy was associated with improved survival in ns-NSCLC specifically in patients with LMs. These hypothesis-generating findings suggest that the benefit may stem from disruption of VEGF-A-driven immunosuppressive signaling in the liver, but require prospective confirmation.